An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)

Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL)

This study will assess the prophylactic effect of pegfilgrastim (Neulastim) on febrile and/or Grade IV neutropenia in participants receiving chemotherapy (CT) or immunochemotherapy (ICT) as first or second line treatment for NHL. Pegfilgrastim will be administered at a fixed dose of 6 milligrams (mg) subcutaneously 24 hours after the last dose of CT or ICT in each treatment cycle.

Inclusion Criteria:

• NHL supported by an Immunohistochemical report
• Eastern Cooperative Oncology Group (ECOG) performance status greater than or equal to (>/=) 2
• Total serum bilirubin less than (<) 2 times upper limit of normal (ULN)
• Absolute neutrophil count (ANC) greater than (>) 2 x10^9 per liter (/L)

Exclusion Criteria:

• Bone marrow compromised > 10 percent (%)
• Any malignant myeloid condition
• Active infections requiring systemic anti-infectious therapies (antibiotics, antifungal drugs, antiviral drugs) within 72 hours prior to CT or ICT initiation
• Known hypersensitivity reactions to Escherichia coli derived products
• Pregnant or nursing participants. Women with childbearing potential should use a safe contraceptive method